Gene Panel Testing For Hereditary Breast Cancer

The primary panel includes 14 genes associated with hereditary breast cancer.

Gene panel testing for hereditary breast cancer.

The myriad myrisk hereditary cancer test is a 35 gene panel that identifies an elevated risk for eight hereditary cancers. Genetic testing does not detect breast cancer itself it identifies people who are at higher than average risk and helps us to determine the best ways to screen them hilliard said. In addition to the primary panel clinicians can also choose to include 14 genes that have preliminary evidence of an association with breast cancer. Genetic testing for hereditary breast and ovarian cancer looks for mutations in the brca1 and brca2 genes.

However some clinicians may wish to include genes that may prove to be clinically significant in the future. This single reliable test provides more information for women suspected to have hereditary cancer predisposition particularly for breast and ovarian cancers. The breast cancer comprehensive panel examines 20 genes associated with an increased risk for hereditary breast cancer. Is ideal for patients with a clinical suspicion of hereditary breast or ovarian cancer who only wish assessment of genes with established management guidelines.

This panel is designed to detect heritable germline mutations and should not be used for the detection of somatic mutations in tumor tissue. This test includes both well established breast cancer susceptibility genes as well as candidate genes with limited evidence of an association with breast cancer. Your doctor might suggest testing using a multigene panel which looks for mutations in several genes at the same time including brca1 and brca2. Myriad myrisk captures more mutation carriers than bracanalysis and colaris combined.

At this time the association of these genes with breast cancer remains uncertain. Studies have shown that testing with myriad myrisk increases mutation detection between 40 and 50 percent. A multi gene panel test provides better diagnostic yield compared with a limited brca1 2 genetic test for patients at risk for hereditary breast cancer.